TRVI Trevi Therapeutics Inc

Price (delayed)

$13.95

Market cap

$1.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.32

Enterprise value

$1.96B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 11

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation ...

Highlights
Trevi Therapeutics's quick ratio has surged by 61% YoY and by 25% QoQ
Trevi Therapeutics's debt has decreased by 29% YoY and by 9% from the previous quarter
The equity has surged by 73% year-on-year but it has declined by 6% since the previous quarter
Trevi Therapeutics's net income has decreased by 7% from the previous quarter but it has increased by 3.7% YoY

Key stats

What are the main financial stats of TRVI

TRVI stock price

How has the Trevi Therapeutics stock price performed over time
Intraday
3.72%
1 week
-3.46%
1 month
-2.99%
1 year
112.01%
YTD
11.42%
QTD
16.93%

Financial performance

How have Trevi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$52.77M
Net income
-$45.61M
Gross margin
N/A
Net margin
N/A
Trevi Therapeutics's net income has decreased by 7% from the previous quarter but it has increased by 3.7% YoY
The operating income has contracted by 7% from the previous quarter and by 3.3% YoY

Price vs fundamentals

How does TRVI's price correlate with its fundamentals

Growth

What is Trevi Therapeutics's growth rate over time

Valuation

What is Trevi Therapeutics stock price valuation
P/E
N/A
P/B
10.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 29% YoY
The P/B is 195% above the 5-year quarterly average of 3.4 and 52% above the last 4 quarters average of 6.6
The equity has surged by 73% year-on-year but it has declined by 6% since the previous quarter

Efficiency

How efficient is Trevi Therapeutics business performance
Trevi Therapeutics's return on equity has surged by 58% YoY and by 3.9% QoQ
TRVI's ROA has soared by 55% YoY and by 3.3% from the previous quarter
Trevi Therapeutics's return on invested capital has surged by 55% YoY and by 8% QoQ

Dividends

What is TRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRVI.

Financial health

How did Trevi Therapeutics financials performed over time
The total assets has surged by 68% year-on-year but it has declined by 7% since the previous quarter
Trevi Therapeutics's quick ratio has surged by 61% YoY and by 25% QoQ
Trevi Therapeutics's debt is 100% less than its equity
TRVI's debt to equity has dropped by 100% year-on-year
The equity has surged by 73% year-on-year but it has declined by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.